1. < Prostate Cancer

Using Decipher Genomic Classifier in diagnosis of Prostate Cancer

Posted by waynen @waynen, Mar 5, 2021

For men facing diagnosis of prostate cancer this study might be helpful.

This systematic review evaluated the available evidence supporting the clinical utility of the Decipher genomic classifier (GC). A total of 42 studies and more than 30,000 patients were included. The authors found that GC was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) in 24 studies.

The authors provide consistent evidence that this test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision–making. The utility of the GC is strongest for intermediate-risk prostate cancer and post-prostatectomy decision–making.
– Gautam Jayram, MD

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

Moderator
Colleen Young, Connect Director | @colleenyoung | Mar 7, 2021

Here is a link to the abstract of the study. You have to pay to see the full journal article.
- A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/33293078/

A reliable identifier of which cancers are more or less agressive is a welcome tool in making treatment decisions for men diagnosed with prostate cancer!

REPLY
renogeorge | @renogeorge | Jun 16, 2022

The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether the patient is a candidate foe active surveillance, needs mono therapy or may benefit from intensified treatment. Do any doctors on this site have any experience or thoughts about this test?

REPLY
2 replies
budisnothome | @budisnothome | Jun 17, 2022
In reply to @renogeorge "The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether..." + (show)
@renogeorge

The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether the patient is a candidate foe active surveillance, needs mono therapy or may benefit from intensified treatment. Do any doctors on this site have any experience or thoughts about this test?

Jump to this post

I had a RP in 2019. Genomic testing said 5.9% chance of reoccurring in 10 years. 16 months later cancer came back in lower abdomen lymph nodes. 35 radiation treatments and many problems after. Test is not always accurate.

REPLY
Moderator
Colleen Young, Connect Director | @colleenyoung | Jun 19, 2022
In reply to @renogeorge "The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether..." + (show)
@renogeorge

The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether the patient is a candidate foe active surveillance, needs mono therapy or may benefit from intensified treatment. Do any doctors on this site have any experience or thoughts about this test?

Jump to this post

Welcome @renogeorge. I moved your question to this discussion about the Decipher Prostate Genomic Classifier that @waynen started. Note that Mayo Clinic Connect is a place to connect with other patients.

An update to the NCCN Clinical Practice Guidelines for Oncology in 2021 recommended using the Decipher Prostate genomic classifier to help guide treatment in men with high-risk prostate cancer following radical prostatectomy (RP).

Did you have the genomic testing done?

REPLY
Please sign in or register to post a reply.